A | B | C | D | E | F | G | H | CH | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z | 0 | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9
Clinical data | |
---|---|
Trade names | Wei Ni An |
Other names | Nylestriol; LY-49825; Ethinylestriol cyclopentyl ether; EE3CPE; 17α-Ethynylestriol 3-cyclopentyl ether |
Routes of administration | By mouth |
Drug class | Estrogen; Estrogen ether |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
Chemical and physical data | |
Formula | C25H32O3 |
Molar mass | 380.528 g·mol−1 |
3D model (JSmol) | |
| |
|
Nilestriol (INN ) (brand name Wei Ni An; developmental code name LY-49825), also known as nylestriol (USAN , BAN ), is a synthetic estrogen which was patented in 1971[1] and is marketed in China.[2][3] It is the 3-cyclopentyl ether of ethinylestriol, and is also known as ethinylestriol cyclopentyl ether (EE3CPE).[4] Nilestriol is a prodrug of ethinylestriol, and is a more potent estrogen in comparison.[4] It is described as a slowly-metabolized, long-acting estrogen and derivative of estriol.[5][6] Nilestriol was assessed in combination with levonorgestrel for the potential treatment of postmenopausal osteoporosis, but this formulation ultimately was not marketed.[7]
See also
References
- ^ Official Gazette of the United States Patent and Trademark Office: Patents. U.S. Department of Commerce, Patent and Trademark Office. 1975. p. 1677.
- ^ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 891–. ISBN 978-1-4757-2085-3.
- ^ "Nilestriol". Drugs.com.
- ^ a b McGuire W (14 December 2013). Experimental Biology. Springer Science & Business Media. pp. 161–. ISBN 978-1-4757-4673-0.
- ^ Schoenberg DR (1977). Biochemical Properties of the Cytoplasmic Estrogen Receptors from Immature Rat and Mature Rabbit Uteri (Ph.D. thesis). University of Wisconsin. p. A-17.
- ^ "Section 10: Obstetrics and gynecology". Excerpta Medica. 1978.
- ^ Aronson JK (21 February 2009). Meyler's Side Effects of Endocrine and Metabolic Drugs. Elsevier. pp. 173–. ISBN 978-0-08-093292-7.
>Text je dostupný pod licencí Creative Commons Uveďte autora – Zachovejte licenci, případně za dalších podmínek. Podrobnosti naleznete na stránce Podmínky užití.
Text je dostupný za podmienok Creative
Commons Attribution/Share-Alike License 3.0 Unported; prípadne za ďalších
podmienok.
Podrobnejšie informácie nájdete na stránke Podmienky
použitia.